Stay updated with breaking news from Germany Based Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed higher on Friday, as the S&P/BNY Mellon index... -January 26, 2024 at 05:04 pm EST - MarketScreener
This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower on Tuesday, as the S&P/BNY Mellon index... -January 16, 2024 at 04:55 pm EST - MarketScreener
MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.
BERLIN (AP) — Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival...
MedCity News MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma. Shares0 MorphoSys, a biotech that has spent much of its three-decade history developing drugs that ended up at other companies via partnerships or licensing deals, is now building up its own pipeline through a...